Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Axovant Sciences Ltd (NQ: AXON)
1.900 USD  -0.050 (-2.56%)
Official Closing Price  /  Updated: 5:37 PM EST, Nov 14, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 462,600
Open 1.950
Bid (Size) 1.860 (10)
Ask (Size) 1.980 (10)
Prev. Close 1.950
Today's Range 1.900 - 1.970
52wk Range 1.020 - 6.590
Shares Outstanding 107,788,074
Dividend Yield N/A
Performance
YTD
-64.22%
-64.22%
1 Month
-19.83%
-19.83%
3 Month
-5.94%
-5.94%
6 Month
+53.23%
+53.23%
1 Year
-63.18%
-63.18%
Top News
More News
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON) today provided financial results and corporate updates for its second fiscal quarter ended September 30, 2018. Read More
from GlobeNewswire News Releases
Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease
from GlobeNewswire News Releases
More News
Read More
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
from GlobeNewswire News Releases
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and
from GlobeNewswire News Releases
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
from GlobeNewswire News Releases
Axovant to Present at Two Upcoming Investor Conferences
from GlobeNewswire News Releases
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
from PR Newswire
Axovant to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
from GlobeNewswire News Releases
Analysts Anticipate 40% Gains Ahead For The Holdings of IBB
category ETFs
from ETF Channel
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X